Law360, New York (September 7, 2006, 12:00 AM EDT) -- An International Trade Commission administrative law judge has ruled that Bavarian Nordic's patents for a smallpox vaccine are invalid, which may give rival Acambis a leg up in a battle over millions in U.S. anti-terror funding.
Bavarian Nordic, which brought the complaint against Acambis in August 2005, promptly said it would file an appeal. The complaint involves patents used in the smallpox vaccine Imvamune, which is marketed by Bavarian Nordic.
“In addition to disagreeing with the initial ruling on patent validity we find that the basis...
Acambis Gets Boost With Smallpox Vaccine Ruling
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
